Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by Lerdsin General Hospital.
Recruitment status was  Not yet recruiting
Information provided by:
Lerdsin General Hospital Identifier:
First received: July 29, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown renoprotection whether it was used alone or in combination. Aliskiren is a direct renin inhibitor (DRI) that has shown renal benefits and safety when combined with ARB. However, to date, the safety of add on aliskiren to the combination treatment of ACEI and ARB in diabetic nephropathy patients remains to elucidate.

Condition Intervention Phase
Type 2 Diabetes With Nephropathy
Drug: Aliskiren 300mg/d
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy

Resource links provided by NLM:

Further study details as provided by Lerdsin General Hospital:

Primary Outcome Measures:
  • Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathy [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reduction of systolic blood pressure [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: No ]
  • Reduction of proteinuria [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: No ]
  • Change in GFR/mo [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: Yes ]
  • Change of Serum prorenin level compare to baseline [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: No ]
  • Change of Urinary TGFb1 compare to baseline [ Time Frame: 12 wk after randomization ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: September 2009
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Aliskiren Drug: Aliskiren 300mg/d
Aliskiren 300mg/d v.s. placebo for 12wk
Other Name: Rasilez (Thailand)


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type2 diabetes patients
  • Age <30yrs-70yrs>
  • Overt proteinuria (Urinary protein creatinine ratio > 200mg/g 2 times or more during past 6 Mo)
  • Scr < 2.5 mg/dL
  • HbA1C < 7.5
  • Systolic blood pressure > 160 mmHg without antihypertensive drugs or > 140 with antihypertensive drug
  • No history of previous cardiovascular event (Stroke, Myocardial infarction, unstable angina, hospitalization, surgical correction PVD or PVD with claudication)
  • No hospitalization within 1 yr except for elective surgery

Exclusion Criteria:

  • Physical examination found or suspected serious co-morbid (AF, carotid bruit, structural heart disease, cirrhosis and decompensate liver disease)
  • Non adherence to protocol
  • Intolerable to ACEI or ARB during run-in
  • Abnormal liver function test at the run-in period
  • Rapid declining renal function (SCr increase > 40%) during run-in
  • Hyperkalemia (serum K > 5.5 mEq/L at randomization)
  • Malignancy detected o
  • SBP lower than 110 mmHg (at randomization)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00949351

Contact: Krissanapong Manotham, Dr 662 3539799 ext 2501
Contact: Tanaporn Ratanasuwan, Dr 662 3539799 ext 9722

Lerdsin General Hospital Not yet recruiting
Bangkok, Thailand, 10500
Contact: Krissanapong Manotham, Dr    662 3539799 ext 2501   
Contact: Tanaporn Ratanasuwan, Dr   
Principal Investigator: Krissanapong Manotham, Dr         
Sponsors and Collaborators
Lerdsin General Hospital
  More Information

Responsible Party: Division of Nephrology, Department of Medicine, Lerdsin General Hospital Identifier: NCT00949351     History of Changes
Other Study ID Numbers: Lerdsin 36/52 
Study First Received: July 29, 2009
Last Updated: July 29, 2009
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Lerdsin General Hospital:
ACEI, ARB, DN, aliskiren, proteinuria

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Kidney Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protease Inhibitors processed this record on October 26, 2016